|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0013072,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0079083,
umls-concept:C0210657,
umls-concept:C0282460,
umls-concept:C0456599,
umls-concept:C0796392,
umls-concept:C1327830,
umls-concept:C1518578,
umls-concept:C1696465
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-10-26
|
|
pubmed:abstractText |
: Bevacizumab is approved in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC). Preclinical data suggest that enzastaurin and bevacizumab may have complementary effects in inhibiting angiogenesis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamates,
http://linkedlifedata.com/resource/pubmed/chemical/Guanine,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/enzastaurin,
http://linkedlifedata.com/resource/pubmed/chemical/pemetrexed
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:BradfordDanielD,
pubmed-author:BufillJoseJ,
pubmed-author:CaseyErin MEM,
pubmed-author:FisherWilliamW,
pubmed-author:HannaNasserN,
pubmed-author:HarbWaelW,
pubmed-author:LatzJane EJE,
pubmed-author:LiXiaochunX,
pubmed-author:NattamSreenivasaS,
pubmed-author:PatelJyotiJ,
pubmed-author:WuJingweiJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1815-20
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20881647-Adenocarcinoma,
pubmed-meshheading:20881647-Adrenal Gland Neoplasms,
pubmed-meshheading:20881647-Antibodies, Monoclonal,
pubmed-meshheading:20881647-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20881647-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20881647-Bone Neoplasms,
pubmed-meshheading:20881647-Carboplatin,
pubmed-meshheading:20881647-Double-Blind Method,
pubmed-meshheading:20881647-Female,
pubmed-meshheading:20881647-Glutamates,
pubmed-meshheading:20881647-Guanine,
pubmed-meshheading:20881647-Humans,
pubmed-meshheading:20881647-Indoles,
pubmed-meshheading:20881647-Liver Neoplasms,
pubmed-meshheading:20881647-Lung Neoplasms,
pubmed-meshheading:20881647-Male,
pubmed-meshheading:20881647-Middle Aged,
pubmed-meshheading:20881647-Neoplasm Staging,
pubmed-meshheading:20881647-Placebos,
pubmed-meshheading:20881647-Pleural Neoplasms,
pubmed-meshheading:20881647-Survival Rate,
pubmed-meshheading:20881647-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
|
|
pubmed:affiliation |
Indiana University, Indianapolis, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
